Why Angelini Pharma is acquiring the American company Catalyst
Angelini Pharma officially enters the U.S. market through the acquisition of Catalyst for $4.1 billion. All the details.
What Catalyst does (episode by Angelini Pharma)
According to Bloomberg, Angelini Pharma is targeting the U.S. market with a potential $3.6 billion acquisition of Catalyst Pharmaceuticals, a biopharmaceutical company that has seen a 24% increase in its stock over the past twelve months and holds exclusive rights to therapies for rare diseases. Facts, names, and figures.
Brain health enters the European agenda
In Brussels, during Brain Awareness Week, institutions, experts, and industry discussed European strategies for brain health. Among the speakers, Agnese Cattaneo, CMO of Angelini Pharma, emphasized the importance of a stable and coordinated ecosystem that supports high-risk research and accelerates the transfer of scientific discoveries to patients. All the details
